GlassScriptPhysician profile
Jeffrey S Deitch
NPI 1386634749
$196,766.70
in general payments reported to CMS, 2019-2025
52 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $8,869 · 2021: $20K · 2022: $17K · 2023: $13K · 2024: $22K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Travel and Lodging: $16K · Food and Beverage: $7,918 · Consulting Fee: $3,907 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,408.64 |
| Travel and Lodging | $16,117.75 |
| Food and Beverage | $7,918.44 |
| Consulting Fee | $3,906.75 |
| Education | $205.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $36,501.03 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $34,098.55 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $30,541.47 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $27,843.50 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $26,248.99 | 2019-2022 | |
| Urovant Sciences INC | $18,943.05 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $13,304.25 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $1,913.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,152.86 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $805.34 | 2019-2024 | Jardiance |
| Pfizer INC. | $754.55 | 2019-2025 | |
| Abbvie INC. | $631.27 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $614.66 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $401.25 | 2019-2024 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $400.42 | 2019-2024 |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Deitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.